



VETOQUINOL WINS THE ANIMAL PHARM'S AWARD FOR BEST EUROPEAN COMPANY 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded "Best European Company 2020" by Animal Pharm.

The company was selected thanks to its outstanding year in 2020. According to Animal Pharm, Vetoquinol excelled financially and diversified its product portfolio. Moreover, its performance was made all the more impressive last year by the tough conditions for everyone during the pandemic.

In 2020, Vetoquinol Laboratory reported sales of €427.5 million, up 8.0% and experienced a double-digit sales growth at constant exchange rates. Last summer, Vetoquinol acquired the Profender® and Drontal® product families in the EU and the UK confirming its ambition to become a major player in the parasiticide segment in Europe. Consequently, the company secured a combined organic and external growth in all its strategic territories.

It can be noted Vetoquinol was able to mitigate the impact of the Covid-19 health situation by preserving the health and safety of its employees. Thus, the company maintained its industrial activities and reliably served its customers in 2020.

FOR MORE INFORMATION,
CONTACT:

VETOQUINOL
Xavier Berthet
Director of Group Communications
Tel.: +33 (0)3 84 62 58 77
xavier.berthet@vetoquinol.com

Dirk Wuyts, Europe Managing Director, said *"The extraordinary performance during the undoubtedly most challenging year of the past decade is the fruit of a long road towards Excellence initiated nine years ago. I am very thankful to the teams in Europe for their commitment and dedication. Being fully at the service of our customers and their clients was definitively the right approach to achieve more together."*



ABOUT VETOQUINOL

Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. Since its foundation in 1933, Vetoquinol has been pursuing a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. On December 31st 2020, Vetoquinol employs 2,409 people. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).